<p>BOAN BIOTECH (06955.HK) announced its performance for the fiscal year 2025, with revenue of 785 million RMB, an increase of 8.1% year-on-year. It recorded a net profit of 7.14 million RMB, a decline of 90.2%, with earnings per share of 0.01 RMB. No final dividend will be distributed</p>

588130

159615

159837

<p>BOAN BIOTECH announced its 2025 annual performance, with revenue of 785 million RMB (same below), an increase of 8.1% year-on-year. It recorded a net profit of 7.14 million RMB, a decline of 90.2%, with earnings per share of 0.01 RMB. No final dividend will be distributed</p>

AASTOCKS

ChinaAMC SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

First Trust NYSE Arca Biotech Index Fd

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

BOAN BIOTECH

"Performance" BOAN BIOTECH's annual net profit is 7.14 million RMB, down 90.2%, no dividend declared